Lexitas Forges Retina Research Powerhouse with Strategic Acquisitions

DURHAM, NC – May 19, 2026 – In a significant move set to reshape the landscape of ophthalmic clinical research, Lexitas Pharma Services today announced its acquisition of a trio of specialized companies: Erie Retina Research, CASExERIE, and Element Erie. The deal, orchestrated by Lexitas's parent firm QHP Capital, consolidates a premier clinical research site, a surgical innovation hub, and an advanced imaging center under one roof, creating a formidable, end-to-end platform dedicated to accelerating the development of therapies for retinal diseases.

The acquisition brings the renowned expertise of Dr. David Almeida, MD, MBA, PhD, founder of the acquired entities, into the Lexitas fold. He will assume the newly created role of Chief Retina Strategy Officer, signaling a deep integration of scientific leadership with Lexitas’s established clinical trial operations. This strategic alignment aims to build a comprehensive ecosystem designed to meet the escalating demand for faster, more efficient, and scientifically rigorous trials in the rapidly advancing field of retina therapy.

A Strategic Move to Dominate Retina Research

The global ophthalmology CRO market is characterized by a push towards specialization, and this acquisition positions Lexitas as a dominant force within the high-value retina subspecialty. While larger, generalist CROs maintain ophthalmology divisions, Lexitas is doubling down on a specialized, integrated model. The transaction is not merely an expansion but a strategic fusion of complementary capabilities designed to create a seamless drug development pathway for pharmaceutical and biotech sponsors.

Erie Retina Research, based in Pennsylvania, brings a sterling reputation as one of the nation's leading independent retina research centers. With a portfolio of more than 40 active clinical trials and a history of enrolling over 1,000 patients since 2019, it provides Lexitas with a proven, high-performing clinical site and a substantial patient network. The center's track record of operational excellence, including multiple "First Patient In" recognitions, is a critical asset for sponsors looking to expedite trial timelines.

Complementing this clinical prowess is CASExERIE, an innovation hub focused on surgical training and retina-focused product development. Its inclusion provides a unique infrastructure for testing novel surgical devices and advanced procedures, a crucial component in a field increasingly driven by technological innovation. The third piece of the puzzle, Element Erie, is a dedicated imaging and reading center. By bringing this function in-house, Lexitas can ensure greater consistency, quality, and speed in the analysis of ophthalmic imaging—a critical component for evaluating endpoints in most retina trials. Together, these entities form a cohesive unit that addresses nearly every stage of the retina clinical development lifecycle.

The Almeida Effect: Uniting Science and Operations

At the heart of this strategic integration is Dr. David Almeida, a respected vitreoretinal surgeon and clinician-scientist. His appointment as Chief Retina Strategy Officer underscores a commitment to a "science-first" approach, embedding deep clinical and scientific expertise directly into the operational framework of the CRO. This move is designed to bridge the common gap between the scientific objectives of a trial and its day-to-day execution.

Dr. Almeida’s leadership of Erie Retina Research established a model of efficiency and scientific rigor that will now be scaled across Lexitas's expanded retina division. His background, which includes an MD, MBA, and PhD, equips him with a unique, multifaceted perspective on the clinical, business, and scientific demands of modern drug development. As a leading retinal image reader and grader, his direct involvement in the newly expanded imaging and reading center promises to enhance the quality and reliability of data analysis, providing sponsors with more robust and defensible results.

"We are thrilled to join Lexitas and help shape the future of retina research," said Dr. Almeida. "Together, we are creating a coordinated, world-class retina research engine that brings together scientific expertise, operational excellence, and the infrastructure needed to deliver for sponsors and for patients. This collaboration empowers us to broaden our impact and enhance the way we serve patients and sponsors."

Building a High-Efficiency Clinical Trial Ecosystem

For pharmaceutical sponsors, the primary benefit of this integrated platform lies in enhanced efficiency and predictability. By consolidating services that are often outsourced to multiple vendors—such as site recruitment, surgical training, and image reading—Lexitas aims to streamline trial management, reduce administrative burdens, and mitigate the risk of delays.

The key advantages of this new ecosystem are multi-fold. Expanded patient access is achieved by leveraging Erie Retina Research’s established network, helping to overcome one of the most significant hurdles in clinical trials: slow patient enrollment. Operational efficiency is driven by an integrated infrastructure that reduces variability and hand-off delays between different functional areas. The inclusion of CASExERIE provides specialized expertise in surgical and medical device trials, an area of growing importance in ophthalmology. Finally, the centralized image reading and analysis capabilities from Element Erie ensure high-quality, consistent endpoint evaluation, which is fundamental to trial success.

Jeanne Hecht, CEO of Lexitas Pharma Services, emphasized the transformative nature of the partnership. "This partnership marks a pivotal moment for Lexitas and for the advancement of retina research,” she stated. “By integrating the exceptional capabilities of Erie Retina Research and CASExERIE with our operational platform, we are building a research ecosystem that is faster, more predictable, and more aligned with sponsor needs. Most importantly, it expands access for patients and accelerates progress toward meaningful ophthalmic therapies.”

The Private Equity Playbook in Specialized Medicine

This acquisition is a clear reflection of the investment strategy of QHP Capital, the private equity firm that acquired Lexitas in 2022. QHP's playbook focuses on identifying and investing in growth-oriented healthcare companies within niche, high-demand sectors. By providing strategic capital and operational support, the firm aims to build scaled, market-leading platforms. The firm's focus on pharma services has led to a portfolio of companies designed to improve the efficiency of clinical development.

The move to acquire and integrate Dr. Almeida’s companies is a textbook example of this strategy in action. Rather than simply growing Lexitas organically, QHP has facilitated a transformative acquisition that immediately deepens the CRO’s specialization and erects a significant competitive barrier in the lucrative retina research market. This type of consolidation is a growing trend in the CRO industry, as private equity investors recognize the value in creating highly specialized, full-service providers that can offer a premium, integrated solution to drug developers.

By building a more powerful and efficient research engine, the investment aims to generate returns not only for its stakeholders but also by accelerating the entire R&D process. This strategic consolidation ultimately positions Lexitas to better serve a market hungry for innovation, helping to bring new treatments for debilitating conditions like age-related macular degeneration and diabetic retinopathy to patients more quickly.